Expert recommendations for targeted therapies in advanced NSCLC
Pediatric News ,
Osimertinib is the optimal first-line treatment for stage IV non–small cell lung cancer (NSCLC) with activating EGFR mutations…
Osimertinib is the optimal first-line treatment for stage IV non–small cell lung cancer (NSCLC) with activating EGFR mutations…
ASCO > Lung Cancer ASCO Expert Panel considers changes in evidence over last 3 years for updated guideline by Contributing…
Updated clinical guidance for advanced non-small cell lung cancer (NSCLC) provided additional support for first-line treatment…
Advertisement Paul J. Hesketh, MD AN UPDATE of the ASCO Clinical Practice Guideline covers new medicines for nausea and…
The American Society of Clinical Oncology released updated guidelines for treating advanced non-small cell lung cancer (NSCLC…
The American Society of Clinical Oncology released updated guidelines for treating advanced non-small cell lung cancer (NSCLC…
【字体: 大 中 小 】 www.ebiotrade.com 时间:2017年8月17日 来源:生物通 编辑推荐: 美国临床肿瘤学会(ASCO)近日更新了临床实践指南,阐明了免疫治疗在晚期非小细胞肺癌患者中的作用,并就特定患者的靶向治疗提出了新的建议。ASC…
By The ASCO Post Posted: 8/16/2017 9:47:56 AM Last Updated: 8/16/2017 10:14:36 AM Tweet this page Advertisement An update of…
MedpageToday by Charles Bankhead Senior Associate Editor, MedPage Today August 15, 2017 Patients with PD-L1 positive advanced…